However, while we showed anti-tumor activity in combination with TOP1 inhibitors in vivo in orthotopic PDX models at pharmacologically relevant dosages, the clinical translation of CX-5461 in neuroblastoma is likely to face an unexpected obstacle—as CX-5461’s preferential targeting of TOP2B raises major previously unanticipated safety concerns. This evidence concerns the gene TOP2B and neuroblastoma.